TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Short Interest Update

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) was the target of a large drop in short interest in April. As of April 15th, there was short interest totalling 9,400 shares, a drop of 15.3% from the March 31st total of 11,100 shares. Based on an average daily volume of 7,300 shares, the short-interest ratio is currently 1.3 days.

Institutional Trading of TriSalus Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the company. Context Capital Management LLC acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at about $27,000. Deerfield Management Company L.P. Series C acquired a new position in TriSalus Life Sciences in the third quarter valued at approximately $127,000. MSD Partners L.P. acquired a new position in TriSalus Life Sciences in the third quarter valued at approximately $51,000. Shaolin Capital Management LLC bought a new position in shares of TriSalus Life Sciences during the third quarter valued at approximately $29,000. Finally, Wolverine Asset Management LLC acquired a new stake in shares of TriSalus Life Sciences during the 4th quarter worth approximately $123,000.

TriSalus Life Sciences Stock Performance

TLSIW stock opened at $0.98 on Wednesday. The stock’s 50 day moving average is $1.03 and its two-hundred day moving average is $0.79. TriSalus Life Sciences has a 52-week low of $0.02 and a 52-week high of $1.35.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.